Home » Newsletters » BioWorld Science

BioWorld Science

April 2, 2007

View Archived Issues

Parathyroid hormone (1-84) reduces vertebral fracture risk in postmenopausal women

Novel treatment options for urological disorders claimed in recent patents

Recent patents disclose new therapeutic agents for depression and psychosis

Novel therapeutic options for inflammatory disorders disclosed in recent patents

New treatment strategy for HIV infection disclosed in recent GSK patent

Genentech extends research collaboration with Seattle Genetics

BioCryst updates Fodosine development program

ADH-1 plus melphalan studied for treatment of melanoma

StormBio and Imperial Innovations sign agreement for pandemic flu treatment

Yale scientist receives funding to study nanoparticle therapy for prostate cancer

PF-03187207 begins clinical testing for glaucoma

Oxford BioMedica and sanofi-aventis enter agreement for TroVax

Acuity, Froptix and eXegenics to merge to form Opko

SRI and Blanca to jointly develop Blanca's carbacephem antibiotic drug candidates

MorphoSys and Astellas enter antibody partnership

Positive findings for MN-166 in relapsing MS

AS-1552133 shows improved preclinical cholesterol- and triglyceride-lowering activity

The HER/VEGFR2 inhibitor BMS-690514, a clinical candidate for the treatment of solid tumors

Kyorin's PAA-3352 shows antidiabetic activity in vivo

New experimental approaches in glaucoma therapy

CeNeS files first IND for M6G

Carrington and IVI collaborate on sublingual vaccine development

PRX-302 begins phase I study for BPH

Pieris antitumor activity of VEGF-specific Anticalin in preclinical studies

High concentrations of AR-709 reached in key lung compartments

ACE-393 completes phase I trials for travelers' diarrhea

NDA filing for methylnaltrexone for treatment of opioid-induced constipation

Orencia recommended for approval in E.U. for rheumatoid arthritis

Approvable letter for Nuvigil

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...